NIKKEI 225
38,243.89 -30.16 (-0.08%) HANG SENG
18,155.28 +392.25 (+2.21%) CRUDE OIL
79.58 +0.58 (+0.73%) GOLD FUTURES
2,328.20 +17.20 (+0.74%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,730.50 -2,270.78 (-4.73%)
Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 11.45 |
| Open | 11.47 |
| Bid | 11.50 x 100 |
| Ask | 11.66 x 100 |
| Day's range | 11.31 - 12.39 |
| 52-week range | 3.84 - 14.75 |
| Volume | |
| Avg. volume | 468,095 |
| Market cap | 300.258M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").
- PR Newswire
INOVIO to Participate in Upcoming Investor Conferences in May
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May:
- PR Newswire
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
